Evogene Ltd. (NASDAQ:EVGN – Get Free Report) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 135,100 shares, a growth of 503.1% from the October 31st total of 22,400 shares. Based on an average daily trading volume, of 272,900 shares, the short-interest ratio is currently 0.5 days. Currently, 2.6% of the company’s shares are sold short.
Evogene Stock Performance
EVGN traded up $0.05 on Wednesday, hitting $1.67. 63,501 shares of the company were exchanged, compared to its average volume of 89,250. The company has a market cap of $8.97 million, a PE ratio of -0.36 and a beta of 1.43. Evogene has a 12 month low of $1.44 and a 12 month high of $10.40. The stock’s fifty day moving average is $2.32 and its 200-day moving average is $4.33.
Hedge Funds Weigh In On Evogene
A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Report on Evogene
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Read More
- Five stocks we like better than Evogene
- Why Are Stock Sectors Important to Successful Investing?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Calculate Return on Investment (ROI)
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Ride Out The Recession With These Dividend Kings
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.